 |
41 Diseases |  |
16 Trials |
|
16 Trials |  |
501 News |  |
| «12345678» |
- Sandostatin LAR Depot (octreotide acetate) / Novartis
[VIRTUAL] Factors affecting median PFS in patients with advanced, non-resectable well differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR - real world data () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_360;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- ||| paltusotine (CRN00808) / Crinetics
Enrollment closed, Enrollment change: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (clinicaltrials.gov) - May 6, 2020
P2, N=13, Active, not recruiting, Sponsor: Crinetics Pharmaceuticals Inc.
Funding Has not received any funding. Recruiting --> Active, not recruiting | N=40 --> 13
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment change: Comparison of Lanreotide Autogel (clinicaltrials.gov) - Apr 30, 2020
P3, N=4, Terminated, Sponsor: Ipsen
Recruiting --> Active, not recruiting | N=40 --> 13 N=196 --> 4
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Metastases: SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov) - Apr 30, 2020
P3, N=77, Active, not recruiting, Sponsor: Ipsen
N=196 --> 4 Trial completion date: Feb 2020 --> Aug 2021
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Apr 22, 2020
P4, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Feb 2020 --> Aug 2021 Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Review, Journal: Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement. (Pubmed Central) - Apr 10, 2020
This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
- | Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 7, 2020
P1/2, N=22, Active, not recruiting, Sponsor: Duke University
The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach. Suspended --> Active, not recruiting
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4246;
Suspended --> Active, not recruiting The PRESTO study showed that nurses preferred the user experience of the LAN new syringe over the current OCT LAR syringe across all attributes tested.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe: An International Simulated Use Study (PRESTO) () - Mar 8, 2020 - Abstract #ENETS2020ENETS_24;
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis () - Mar 8, 2020 - Abstract #ENETS2020ENETS_15;
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study () - Mar 8, 2020 - Abstract #ENETS2020ENETS_13;
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results () - Mar 8, 2020 - Abstract #ENETS2020ENETS_6;
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel– Baseline Characteristics () - Mar 8, 2020 - Abstract #ENETS2020ENETS_4;
- Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Signifor LAR (pasireotide) / Novartis
[VIRTUAL] MEDICATIONS FOR ACROMEGALY- COST-UTILITY AND VALUE OF INFORMATION ANALYSIS () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1148;
No second-line treatment is recommended. Significant uncertainty of parameters impairs optimal decision-making, and this conclusion can be generalized to other countries.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial suspension: PLANET: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Feb 17, 2020
P1/2, N=26, Suspended, Sponsor: Duke University
Significant uncertainty of parameters impairs optimal decision-making, and this conclusion can be generalized to other countries. Recruiting --> Suspended
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Retrospective data, Journal: Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. (Pubmed Central) - Feb 9, 2020
Lanreotide autogel is a long-acting somatostatin analogue with proven efficacy and safety in patients with well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) in a prior randomized phase III trial (CLARINET)...Hepatic tumor volume > 25% and prior systemic therapy were significantly associated with poorer PFS in the multivariate analysis. Lanreotide is well-tolerated and effective for Korean patients with GEP-NETs in the daily practice setting.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Local myofascitis: An unusual adverse reaction to lanreotide autogel injection. (Pubmed Central) - Feb 7, 2020
Lanreotide is well-tolerated and effective for Korean patients with GEP-NETs in the daily practice setting. No abstract available
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Somatuline LA (lanreotide suspension intramuscular) / Ipsen, Teijin
Retrospective data, Journal: ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. (Pubmed Central) - Dec 20, 2019
No abstract available Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, Metastases: CLARINET FORTE: Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel (clinicaltrials.gov) - Dec 20, 2019
P2, N=99, Completed, Sponsor: Ipsen
Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals. Active, not recruiting --> Completed
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion date, Trial primary completion date, HEOR: OPERA: Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel (clinicaltrials.gov) - Dec 20, 2019
P=N/A, N=115, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Trial completion date: Dec 2019 --> Apr 2020 | Trial primary completion date: Dec 2019 --> Apr 2020
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Long-term safety and efficacy of lanreotide treatment in Japanese patients with neuroendocrine tumors: Final analysis of a phase II open-label extension study. (Level 1, West Hall - Poster Board G2) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_584;
Lanreotide was effective over long-term treatment in Japanese patients with NETs. Clinical trial information: JapicCTI-132375, JapicCTI-142698.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial. (Pubmed Central) - Nov 24, 2019
P3
The purpose of this analysis of patient-reported outcomes from the ELECT (Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment) trial (NCT00774930) was to explore the effect of lanreotide on symptoms of carcinoid syndrome...The higher response rates in the diarrhea burden are consistent with the previously reported effects of lanreotide on octreotide rescue medication use, while the findings of a greater efficacy of lanreotide vs placebo in the quality-of-life domains represent a novel aspect in the benefits of lanreotide. ClinicalTrials.gov identifier: NCT00774930.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET). (Pubmed Central) - Nov 7, 2019
SSA choice did not appear to affect patients' HRQoL. Some patients treated with octreotide were unaware of an SSA with the flexibility of self-injection.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial termination, HEOR, Combination therapy: QoL in IMBO: Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - Oct 1, 2019
P2, N=43, Terminated, Sponsor: Ipsen
Some patients treated with octreotide were unaware of an SSA with the flexibility of self-injection. Completed --> Terminated; The study was terminated early due to insufficient recruitment.
- | cimdelirsen (IONIS-GHR-LRx) / Ionis
Enrollment change: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (clinicaltrials.gov) - Sep 24, 2019
P2, N=60, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Completed --> Terminated; The study was terminated early due to insufficient recruitment. N=42 --> 60
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. (Pubmed Central) - Sep 16, 2019
Treatment with lanreotide depot was associated with significant reductions in the percentages of days patients reported symptoms of diarrhea and flushing, as well as reductions in the frequency and severity of daily symptoms compared with placebo during 16 weeks of double-blind treatment. These improvements were sustained for 32 additional weeks of open-label lanreotide treatment (i.e., through week 48 of treatment), resulting in clinically meaningful, long-term symptom reduction.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2498;
P2
The cohort is representative of typical patients requiring treatment intensification due to progressive panNET or midgut NET. Final analyses are expected in Q1 2020, which will provide efficacy and safety data on use of LAN 120 mg at an increased dosing frequency.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment change, Trial withdrawal, Metastases: NETways: Study to Assess the Use of Lanreotide Autogel (clinicaltrials.gov) - Aug 6, 2019
P=N/A, N=0, Withdrawn, Sponsor: Ipsen
Final analyses are expected in Q1 2020, which will provide efficacy and safety data on use of LAN 120 mg at an increased dosing frequency. N=271 --> 0 | Not yet recruiting --> Withdrawn
- | cimdelirsen (IONIS-GHR-LRx) / Ionis
Enrollment open: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (clinicaltrials.gov) - Jul 28, 2019
P2, N=42, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
N=271 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, Combination therapy: ATLANT: Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (clinicaltrials.gov) - Jul 25, 2019
P2, N=40, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Metastases: Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (clinicaltrials.gov) - Jul 24, 2019
P=N/A, N=196, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Preclinical, Journal: Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1). (Pubmed Central) - Jun 26, 2019
Long-acting somatostatin analogues may be an effective chemopreventive approach to delay the progression of MEN1-associated pNENs. After our preclinical results, we would recommend to evaluate the effects of long-acting SSA in a prospective clinical trial.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: CLARINET FORTE: Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel (clinicaltrials.gov) - May 31, 2019
P2, N=99, Active, not recruiting, Sponsor: Ipsen
After our preclinical results, we would recommend to evaluate the effects of long-acting SSA in a prospective clinical trial. Recruiting --> Active, not recruiting | Trial completion date: Feb 2020 --> Nov 2019 | Trial primary completion date: Feb 2020 --> Nov 2019
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal: Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. (Pubmed Central) - May 30, 2019
Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial primary completion date, Metastases: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (clinicaltrials.gov) - May 30, 2019
P2, N=6, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
These data suggest a need for better monitoring of comorbidities in US acromegaly patients. Trial primary completion date: Apr 2019 --> Apr 2020
- || cimdelirsen (IONIS-GHR-LRx) / Ionis
New P2 trial: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (clinicaltrials.gov) - May 29, 2019
P2, N=42, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, Metastases: Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET (clinicaltrials.gov) - May 20, 2019
P4, N=28, Recruiting, Sponsor: Samsung Medical Center
Trial primary completion date: Apr 2019 --> Apr 2020 Trial primary completion date: Feb 2019 --> Feb 2020
- |||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, Metastases: Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (clinicaltrials.gov) - May 12, 2019
P, N=196, Not yet recruiting, Sponsor: Ipsen
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New P2 trial, Metastases: LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov) - May 9, 2019
P2, N=40, Not yet recruiting, Sponsor: Antonio Fojo
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. (Pubmed Central) - Apr 26, 2019
P3
Trial primary completion date: Feb 2019 --> Feb 2020 TGR provides valuable information on tumor activity and prognosis in patients with metastatic intestinal/pancreatic NETs, and identifies early lanreotide depot/autogel antitumor activity.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Journal, HEOR: LanroNET - A Non-Interventional Prospective Study to Assess the Resource Utilization and Cost of Lanreotide Autogel 120 mg in Population of Polish Patients with Symptomatic Neuroendocrine Tumors. (Pubmed Central) - Apr 17, 2019
TGR provides valuable information on tumor activity and prognosis in patients with metastatic intestinal/pancreatic NETs, and identifies early lanreotide depot/autogel antitumor activity. LanroNET is the first two-year observational study of patients with symptomatic NET evaluating the cost of every-day clinical practice and lanreotide autogel treatment in Poland.
- |||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
New trial, Metastases: NETways: Study to Assess the Use of Lanreotide Autogel (clinicaltrials.gov) - Mar 29, 2019
P, N=271, Not yet recruiting, Sponsor: Ipsen
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Trial primary completion date, Metastases: CLARINET FORTE: Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel (clinicaltrials.gov) - Mar 4, 2019
P2, N=100, Recruiting, Sponsor: Ipsen
LanroNET is the first two-year observational study of patients with symptomatic NET evaluating the cost of every-day clinical practice and lanreotide autogel treatment in Poland. Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Oct 2019 --> Feb 2020
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment change, Trial completion date, Trial primary completion date, Metastases: SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov) - Mar 4, 2019
P3, N=77, Active, not recruiting, Sponsor: Ipsen
Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Oct 2019 --> Feb 2020 N=216 --> 77 | Trial completion date: Aug 2019 --> Feb 2020 | Trial primary completion date: Aug 2019 --> Feb 2020
- || paltusotine (CRN00808) / Crinetics
New P2 trial: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (clinicaltrials.gov) - Jan 3, 2019
P2, N=40, Recruiting, Sponsor: Crinetics Pharmaceuticals Inc.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Trial primary completion date, Metastases: Community-based Neuroendocrine Tumor (NET) Research Study (clinicaltrials.gov) - Dec 24, 2018
P=N/A, N=100, Active, not recruiting, Sponsor: Ipsen
N=216 --> 77 | Trial completion date: Aug 2019 --> Feb 2020 | Trial primary completion date: Aug 2019 --> Feb 2020 Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> May 2020
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Clinical, Review, Journal: An update of lanreotide acetate for treatment of adults with carcinoid syndrome. (Pubmed Central) - Nov 27, 2018
These compounds have shown dramatic responses in symptom control and reduction of serotonin metabolites including urinary 5-hydroxyindoleacetic acid (5-HIAA) levels. This review researches the origins of carcinoid tumors, the development of lanreotide as a treatment and future directions for the treatment of carcinoid syndrome.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula (clinicaltrials.gov) - Oct 12, 2018
P2, N=123, Recruiting, Sponsor: University of Washington
This review researches the origins of carcinoid tumors, the development of lanreotide as a treatment and future directions for the treatment of carcinoid syndrome. Not yet recruiting --> Recruiting | Trial completion date: Oct 2021 --> Apr 2021 | Initiation date: Oct 2017 --> Feb 2018 | Trial primary completion date: Oct 2020 --> Apr 2020
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed, Metastases: SPINET: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (clinicaltrials.gov) - Aug 24, 2018
P3, N=216, Active, not recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting | Trial completion date: Oct 2021 --> Apr 2021 | Initiation date: Oct 2017 --> Feb 2018 | Trial primary completion date: Oct 2020 --> Apr 2020 Recruiting --> Active, not recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, P3 data, Retrospective data, Journal: BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS. (Pubmed Central) - Aug 8, 2018
This pooled analysis of 2 randomized, placebo-controlled trials demonstrated that 5-HIAA and CgA are secreted as biochemical biomarkers in many patients with NETs, regardless of clinical syndromes. Significant biochemical response was associated with improved clinical outcomes, as measured by improved PFS or improved CS symptom control.